Figure 9

Imaging modalities delivery of RNAi therapeutics in cancer therapy and clinical applications

Loutfy H Madkour*

Published: 04 March, 2021 | Volume 5 - Issue 1 | Pages: 005-034

Ultrasound imaging. (a) A schematic illustration of the basic principle of in vivo ultrasound imaging. First, the ultrasound contrast agent that encapsulates RNAi therapeutics is injected into animals, then high-frequency sound waves are sent and penetrated into the subjects, while the time intervals of subsequent reflection of sound waves is recorded by a transducer. The detected signals are converted and constructed into images. A coupling medium is usually used between the contact surface of transducer and subject for sound wave transmission. (b) Typical contrast agents for ultrasound, such as liposome, nanobubble, nanodroplet, and microbubble. (c) Ultrasound-triggered destruction of siRNA-incorporated microbubbles. Ultrasound could disrupt the contrast agents with high acoustic pressure to release RNAi agents when delivered to the blood vessels of the tumor region. Then the released RNAi agents enter into tumor cells to silence target gene.

" alt="jro-aid1035-g009"class="img-responsive img-rounded " style="cursor:pointer">

Figure 9:

Ultrasound imaging. (a) A schematic illustration of the basic principle of in vivo ultrasound imaging. First, the ultrasound contrast agent that encapsulates RNAi therapeutics is injected into animals, then high-frequency sound waves are sent and penetrated into the subjects, while the time intervals of subsequent reflection of sound waves is recorded by a transducer. The detected signals are converted and constructed into images. A coupling medium is usually used between the contact surface of transducer and subject for sound wave transmission. (b) Typical contrast agents for ultrasound, such as liposome, nanobubble, nanodroplet, and microbubble. (c) Ultrasound-triggered destruction of siRNA-incorporated microbubbles. Ultrasound could disrupt the contrast agents with high acoustic pressure to release RNAi agents when delivered to the blood vessels of the tumor region. Then the released RNAi agents enter into tumor cells to silence target gene.

Read Full Article HTML DOI: 10.29328/journal.jro.1001035 Cite this Article Read Full Article PDF

More Images

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?